|
|
||||||||
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina
Submitted 12 July 2007 ; accepted in final form 4 August 2007
The interaction of renal basolateral organic anion transporter 3 (Oat3) with commonly used pharmacotherapeutics (e.g., NSAIDs,
-lactams, and methotrexate) has been studied extensively in vitro. However, the in vivo role of Oat3 in drug disposition, in the context of other transporters, glomerular filtration, and metabolism, has not been established. Moreover, recent investigations have identified inactive human OAT3 polymorphisms. Therefore, this investigation was designed to elucidate the in vivo role of Oat3 in the disposition of penicillin G and prototypical substrates using an Oat3 knockout mouse model. Oat3 deletion resulted in a doubling of penicillin's half-life (P < 0.05) and a reduced volume of distribution (P < 0.01), together yielding a plasma clearance that was one-half (P < 0.05, males) to one-third (P < 0.001, females) of that in wild-type mice. Inhibition of Oat3 abolished the differences in penicillin G elimination between genotypes. Hepatic accumulation of penicillin was 2.3 times higher in male knockouts (P < 0.05) and 3.7 times higher in female knockouts (P < 0.001). Female knockouts also exhibited impaired estrone-3-sulfate clearance. Oat3 deletion did not impact p-aminohippurate elimination, providing correlative evidence to studies in Oat1 knockout mice that suggest Oat1 governs tubular uptake of p-aminohippurate. Collectively, these findings are the first to indicate that functional Oat3 is necessary for proper elimination of xenobiotic and endogenous compounds in vivo. Thus Oat3 plays a distinct role in determining the efficacy and toxicity of drugs. Dysfunctional human OAT3 polymorphisms or instances of polypharmacy involving OAT3 substrates may result in altered systemic accumulation of
-lactams and other clinically relevant compounds.
kidney; liver; transport; Oat1; drug disposition
This article has been cited by other articles:
![]() |
V. Vallon, S. A. Eraly, W. R. Wikoff, T. Rieg, G. Kaler, D. M. Truong, S.-Y. Ahn, N. R. Mahapatra, S. K. Mahata, J. A. Gangoiti, et al. Organic Anion Transporter 3 Contributes to the Regulation of Blood Pressure J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1732 - 1740. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. VanWert, C. Srimaroeng, and D. H. Sweet Organic Anion Transporter 3 (Oat3/Slc22a8) Interacts with Carboxyfluoroquinolones, and Deletion Increases Systemic Exposure to Ciprofloxacin Mol. Pharmacol., July 1, 2008; 74(1): 122 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, V. Vallon, T. Rieg, J. A. Gangoiti, W. R. Wikoff, G. Siuzdak, B. A. Barshop, and S. K. Nigam Multiple organic anion transporters contribute to net renal excretion of uric acid Physiol Genomics, April 21, 2008; 33(2): 180 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vallon, T. Rieg, S. Y. Ahn, W. Wu, S. A. Eraly, and S. K. Nigam Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics Am J Physiol Renal Physiol, April 1, 2008; 294(4): F867 - F873. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |